The data shows a consistent decline in cardiovascular system medicine sales in Canada from 2024 to 2028, dropping from 66.5 to 62.5 US Dollars PPP per capita. In 2023, this figure was 67.7. The year-on-year decline from 2024 onward averages around 2%, suggesting a steady decrease. The CAGR from 2024 to 2028 is approximately -1.55%, signaling a continuous reduction in per capita spending on cardiovascular medicines.
Looking forward, key trends to watch include increased generics competition, cost pressures from healthcare systems aiming to reduce spending, and potential breakthroughs in cardiovascular treatments that could alter cost dynamics. Innovation in personalized medicine could also reshape market demand.
